68 related articles for article (PubMed ID: 15086416)
1. Establishment of a pluripotent preleukaemic stem cell line by expression of the AML1-ETO fusion protein in Notch1-immortalized HSCN1cl10 cells.
Delaney C; Bernstein ID
Br J Haematol; 2004 May; 125(3):353-7. PubMed ID: 15086416
[TBL] [Abstract][Full Text] [Related]
2. Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2.
Kohzaki H; Ito K; Huang G; Wee HJ; Murakami Y; Ito Y
Oncogene; 1999 Jul; 18(28):4055-62. PubMed ID: 10435586
[TBL] [Abstract][Full Text] [Related]
3. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
4. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells.
Nimer SD; Moore MA
Oncogene; 2004 May; 23(24):4249-54. PubMed ID: 15156180
[TBL] [Abstract][Full Text] [Related]
5. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro.
Senyuk V; Li D; Zakharov A; Mikhail FM; Nucifora G
Cancer Res; 2005 Sep; 65(17):7603-11. PubMed ID: 16140925
[TBL] [Abstract][Full Text] [Related]
6. AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain.
Wei H; Liu X; Xiong X; Wang Y; Rao Q; Wang M; Wang J
FEBS Lett; 2008 Jun; 582(15):2167-72. PubMed ID: 18519037
[TBL] [Abstract][Full Text] [Related]
7. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
8. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
[TBL] [Abstract][Full Text] [Related]
9. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
Peterson LF; Lo MC; Okumura AJ; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
[TBL] [Abstract][Full Text] [Related]
10. Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1.
Choi Y; Elagib KE; Delehanty LL; Goldfarb AN
Cancer Res; 2006 Mar; 66(6):2990-6. PubMed ID: 16540647
[TBL] [Abstract][Full Text] [Related]
11. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
[TBL] [Abstract][Full Text] [Related]
12. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model.
Fischer M; Schwieger M; Horn S; Niebuhr B; Ford A; Roscher S; Bergholz U; Greaves M; Löhler J; Stocking C
Oncogene; 2005 Nov; 24(51):7579-91. PubMed ID: 16044150
[TBL] [Abstract][Full Text] [Related]
13. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
14. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal.
Tonks A; Tonks AJ; Pearn L; Pearce L; Hoy T; Couzens S; Fisher J; Burnett AK; Darley RL
Leukemia; 2004 Jul; 18(7):1238-45. PubMed ID: 15152269
[TBL] [Abstract][Full Text] [Related]
15. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells.
Li X; Xu YB; Wang Q; Lu Y; Zheng Y; Wang YC; Lübbert M; Zhao KW; Chen GQ
J Cell Physiol; 2006 Sep; 208(3):594-601. PubMed ID: 16741927
[TBL] [Abstract][Full Text] [Related]
16. The 8;21 translocation in leukemogenesis.
Peterson LF; Zhang DE
Oncogene; 2004 May; 23(24):4255-62. PubMed ID: 15156181
[TBL] [Abstract][Full Text] [Related]
17. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
Xu M; Li D; Lu Y; Chen GQ
Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
[TBL] [Abstract][Full Text] [Related]
18. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO.
Lausen J; Liu S; Fliegauf M; Lübbert M; Werner MH
Oncogene; 2006 Mar; 25(9):1349-57. PubMed ID: 16247445
[TBL] [Abstract][Full Text] [Related]
19. ETO interacting proteins.
Hug BA; Lazar MA
Oncogene; 2004 May; 23(24):4270-4. PubMed ID: 15156183
[TBL] [Abstract][Full Text] [Related]
20. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]